Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
N Kemeny, Y Huang, A M Cohen...
https://pubmed.ncbi.nlm.nih.gov/10615075/Actively Recruiting
Led by AdventHealth · Updated on 2026-09-29
10
Participants Needed
1
Research Sites
N/A
Total Duration
This observational study evaluates the use of hepatic artery infusion pump HAIP chemotherapy in patients with pancreatic or duodenal adenocarcinoma who have isolated or liver-dominant metastases following surgery and systemic chemotherapy. The study aims to assess liver tumor response using imaging criteria RECIST and measure outcomes such as progression-free survival and overall survival. It is a prospective feasibility study enrolling adult patients with confirmed diagnoses who are appropriate candidates for HAIP treatment. Participants will undergo placement of a hepatic artery infusion pump as part of their standard clinical care. They will receive floxuridine FUDR-based chemotherapy delivered through the pump. This study does not introduce experimental treatments but collects data during routine care. Treatment decisions including timing and regimen are made by the treating oncology team. Participants will be followed for up to five years after pump placement to track long-term outcomes. During the study, clinical data including imaging results, laboratory tumor markers such as ctDNA, CEA, and CA 19-9, and treatment details will be collected from medical records. There are no additional study-specific visits or procedures beyond standard care. The research team will measure progression-free survival, hepatic disease control rate, overall survival, and monitor complications related to surgery, catheter use, and chemotherapy. Data privacy will be maintained through de-identification and secure storage.
CONDITIONS
Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma
M
Maggie Polanco, RN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AdventHealth
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 5 years
Participants receive hepatic artery infusion pump placement and floxuridine chemotherapy as part of their standard care. Clinical data and laboratory results will be collected over time from medical records without additional study visits.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
N Kemeny, Y Huang, A M Cohen...
https://pubmed.ncbi.nlm.nih.gov/10615075/Yutaro Kato, Akira Tsuyuki, Kiyoshi Kikuchi...
https://pubmed.ncbi.nlm.nih.gov/15816615/Shinya Endo, Shinya Kawaguchi, Shuzo Terada...
https://pubmed.ncbi.nlm.nih.gov/32963157/Aya Hashimoto, Hideyuki Nishiofuku, Toshihiro Tanaka...
https://pubmed.ncbi.nlm.nih.gov/22451562/AdventHealth
Lead Sponsor